Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SERF1AP1, or Small EDRK-rich factor 1A pseudogene 1, is classified as a **pseudogene**, meaning it is a DNA sequence that resembles a functional gene but is generally non-coding and does not produce a functional protein product[3][6]. Pseudogenes such as SERF1AP1 are relics of evolutionary genomic processes and typically lack biological activity. While it is recognized that some human pseudogenes can exert regulatory functions, such as influencing gene expression via non-coding RNA mechanisms, there is no evidence in current scientific literature that SERF1AP1 has any such roles[3][2][5][6].\n\nSERF1AP1 is distinct from the parental gene "SERF1A" (Small EDRK-rich factor 1A), which may have protein-coding function in other contexts or organisms, but SERF1AP1 itself is specifically marked as a pseudogene[6].\nNo human disease or drug interaction data are related to SERF1AP1 at this time[3].\nThis pseudogene does not have homologs in humans or most mammals, as per some genome databases, further highlighting its lack of functional significance in human biology[6].\nThe term "EDRK-rich" refers to the amino acid composition (glutamic acid, aspartic acid, arginine, lysine), but this is historical/structural annotation and does not imply that the pseudogene produces a functional peptide[3][6].\n\nSERF1AP1 should not be considered a therapeutic target, biomarker, or subject to safety concerns. Its role is limited to being a genomic element without known biological or clinical relevance in current literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small EDRK-rich factor 1A pseudogene 1 (SERF1AP1).